98%
921
2 minutes
20
Background: It has been reported that the average activity of coagulation factor XII depends on the ethnicity of the population under study but little information is available on Chinese. We here provide an analysis of the range of activities and antigenic levels of factor XII in healthy Han Chinese and correlate the measurements with polymorphisms and mutations in the corresponding gene.
Methods: Plasma samples were obtained from 549 healthy Chinese adults (264 men, 285 women; age 16-79years) undergoing routine check-ups. The samples were subjected to an activated partial thromboplastin time-based factor XII activity assay as well as an enzyme-linked immunosorbent assay. Partial gene sequence analyses were performed in subjects with low factor XII activity and in normal controls.
Results: Ninety-five percent of the subjects had factor XII activities between 47% and 160.25%, with no evidence for an influence of sex or age. Among 15 subjects with activity levels ≤47%, we found one novel nonsense and two missense mutations that may lead to dysfunctional proteins. No mutations were found in a selection of subjects with activities above 47%. Interestingly, however, the particular sequence at a known C/T polymorphism at position 46 just upstream of the translational start codon was correlated with factor XII activity. Subjects homozygous for the T allele, which has an allelic frequency of 0.69, showed significantly lower factor XII activities compared to subjects homozygous for the C allele or those heterozygous for C/T.
Conclusions: The survey determined the normal range of factor XII activities in healthy Chinese and identified mutations as well as a biased representation of a polymorphic nucleotide in subjects with abnormally low activities. The results provide an essential basis for the diagnosis of FXII deficiencies in Chinese.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.thromres.2015.06.012 | DOI Listing |
J Clin Pharmacol
September 2025
CSL Behring LLC, King of Prussia, PA, USA.
Garadacimab is a novel, fully human, anti-activated factor XII monoclonal antibody approved for long-term prophylaxis of patients with hereditary angioedema. This open-label, parallel-group, Phase 1, single-center, bridging study in healthy adults (18-55 years of age) characterized the pharmacokinetics and safety of a single 200 mg subcutaneous injection of garadacimab administered via autoinjector/pre-filled pen (AI/PFP) compared with the pre-filled syringe (PFS) used in previous studies. The aim of the study was to bridge the understanding of the PK and safety of garadacimab between PFS and AI/PFP modes of administration.
View Article and Find Full Text PDFInt J Lab Hematol
September 2025
Service d'Hématologie Biologique, Clermont-Ferrand, France.
Background: Preanalytical conditions, particularly centrifugation protocols, are critical for producing high-quality platelet-poor plasma in hemostasis testing. Centrifuge braking is debated due to its potential impact on platelet remixing.
Objectives: To evaluate the effect of centrifuge braking on residual platelet counts and a broad panel of hemostasis assays using both fresh and double-centrifuged plasma.
Hematology
December 2025
Department of Orthopedics, Jiaxing Second Hospital, Jiaxing, People's Republic of China.
Deep vein thrombosis (DVT), a prevalent vascular disorder driven by venous stasis, endothelial injury, and hypercoagulability, imposes a significant global health burden due to life-threatening complications like pulmonary embolism. Recent advances highlight inflammation as a pivotal contributor to DVT pathogenesis, intricately linked with coagulation through immunothrombosis. This review synthesizes emerging molecular targets bridging these pathways, focusing on neutrophil extracellular traps (NETs), peptidylarginine deiminase 4 (PAD4), P-selectin, high-mobility group box 1 (HMGB1), tissue factor (TF), complement C3, and the NLRP3 inflammasome.
View Article and Find Full Text PDFNat Commun
September 2025
Cardiovascular Disease Initiative, The Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Coagulation factor XII has been identified as a potential drug target that could prevent thrombosis without increasing the risk of bleeding. However, human data to support the development of factor XII-directed therapeutics are lacking. To assess the role of factor XII in venous thromboembolism, we examine genetic variation in the coding region of the F12 locus across 703,745 participants in the UK Biobank and NIH All of Us biorepositories.
View Article and Find Full Text PDFJ Clin Med
August 2025
Discipline of Genetics, Department of Microscopic Morphology, Genomic Medicine Centre "Victor Babes", University of Medicine and Pharmacy, 300041 Timisoara, Romania.
: Chronic low-grade inflammation drives cardiometabolic risk; functional SNPs may influence individual cytokine and hematologic phenotypes. We investigated genotype-specific relationships between circulating immuno-inflammatory biomarkers and routine blood indices in apparently healthy adults. : In this cross-sectional study, 155 fasting volunteers (26-72 years) were genotyped for and .
View Article and Find Full Text PDF